Objective To explore the clinical effect of Xuebijing Injection on severe acute pancreatitis and its regulating effect on the level of inflammatory factors. Methods A total of 60 patients with severe pancreatitis admitted to our hospital from July 2019 to September 2020 were selected as the research objects, and they were divided into the control group (30 cases) and the experimental group (30 cases) using the parity number assignment method. The control group was treated with conventional treatment, and the experimental group was treated with conventional treatment combined with Xuebijing treatment plan. Time of hospitalization, inflammatory factor levels, incidence of adverse reactions, and mortality were compared between the two groups. Results Before treatment, there was no significant difference in the levels of interleukin-6 (IL-6), serum C-reactive protein (hs-CRP), and tumor necrosis factor-α (TNF-α) between the two groups of patients (P＞0.05). After treatment, the IL-6, hs-CRP and TNF-α in the experimental group were lower than those in the control group, and the differences were statistically significant (P＜0.05). The maintenance time of mechanical ventilation, intensive care unit (ICU) stay, and hospital stay in the experimental group were shorter than those in the control group, and the total incidence of adverse reactions and mortality in the experimental group were lower than those in the control group, the differences were statistically significant (P＜0.05). Conclusion On the basis of conventional treatment, the application of Xuebijing Injection for treatment can help to improve the inflammatory indexes of patients with severe acute pancreatitis, which is beneficial to improve the treatment effect, shorten the length of hospitalization, and the curative effect is positive. It is worthy of promotion.